



## Media Releases » **Torrent Pharma announces Q1 FY 2015-16 Results** July 27th, 2015

Financial Highlights	Q1 FY 15-16	Q1 FY 14-15	Growth
Revenues	1,947	1,114	75%
EBITDA	974	380	156%
% Revenues	50%	34%	
PBT	859	349	146%
% Revenues	44%	31%	
PAT	449	256	75%
% Revenues	23%	23%	
EPS	26.5	16.1	75%

All amounts in ₹ crs except per share data

Ahmedabad based Pharmaceuticals major, Torrent Pharmaceuticals Limited, today released its financial results for the Quarter ended 30th June, 2015.

### Quarterly Financials

- For Q1 FY 2015-16 revenues were at Rs. 1,947 crores up by 75% from Rs. 1,114 crores during the same period last year.
- EBITDA for Q1FY 2015-16 was at Rs.974 crores up by 156% from Rs. 380 crores during the same period last year.
- PAT for Q1 2015-16 was at Rs. 449 crores up by 75% from Rs.256 crores during the same period last year.
- The exceptional growth in the revenues and profits for the quarter is primarily on account of the launch of a new product in US market, which currently has limited competition. The continuation of this is dependent on competitive market conditions.

### PERFORMANCE HIGHLIGHTS

#### BRANDED GENERICS

##### India Business

- Domestic formulation business recorded revenues of Rs. 491 crores for Q1 FY2015-16 growing by 39%.
- As per AIOCD, the domestic formulation business growth was 28% compared to covered market growth of 14% for Q1 FY 2015-16. (AIOCD Dataset June 2015)

#### GENERICS

##### USA

- Revenues from US operations for Q1 2015-16 registered growth of 231%.

#### About Torrent Pharma

Torrent Pharma, with annual revenues of almost Rs. 4700 crores is the flagship Company of the Torrent Group. Torrent continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands(AIOCD Dataset).

Torrent has a full equipped Research Center, employing almost 600 scientists, to support the Company's operations and product pipeline for both Domestic and Overseas markets. The Company's manufacturing plants located at Indrad, Baddi & Sikkim have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.